Figure 1

DAB/IL2 transiently depletes CD4⁺ and CD8⁺ T cells in melanoma patients. 10 patients with stage IV metastatic melanoma were administered DAB/IL2 (intravenous; 12 μg/kg) daily × 4 days (arrows indicate each administration). Whole blood was collected on the indicated days and analyzed for absolute lymphocyte (black), granulocyte (red) and monocyte (green) concentration with an automated hematology analyzer (A) and absolute CD4⁺ and CD8⁺ T cell concentration by flow cytometry (B). The peripheral blood concentrations of CD4⁺ and CD8⁺ T cells were quantified by multiplying the percentage of anti-CD4 or anti-CD8 fluorescence-positive cells within the lymphocyte forward/side scatter gate by the absolute lymphocyte concentration determined using an automated hematology analyzer. Percent control of each sample was calculated by dividing the absolute cell concentration on the indicated day of treatment with the absolute cell concentration on day 0 prior to DAB/IL2 administration (× 100). Data are represented as averages ± standard error of the mean (n = 10 patients).